Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
Maze Therapeutics (NASDAQ:MAZE) has appointed Misbah Tahir as Chief Financial Officer, effective immediately. Tahir brings over 20 years of biopharmaceutical industry experience, most recently serving as CFO at IGM Biosciences where he led the company's IPO and raised over $1 billion in financing.
The appointment comes as Maze prepares for key clinical milestones, including MZE782 data in phenylketonuria and chronic kidney disease in Q3 2025 and Phase 2 HORIZON trial data of MZE829 in APOL1-mediated kidney disease in Q1 2026. The company maintains a strong financial position with cash runway extending into 2H 2027.
Maze Therapeutics (NASDAQ:MAZE) ha nominato con effetto immediato Misbah Tahir come Chief Financial Officer. Tahir vanta oltre 20 anni di esperienza nell'industria biofarmaceutica e, più recentemente, è stato CFO di IGM Biosciences, dove ha guidato l'IPO dell'azienda e raccolto oltre 1 miliardo di dollari di finanziamenti.
La nomina avviene mentre Maze si prepara a traguardi clinici chiave, tra cui i dati su MZE782 per fenilchetonuria e malattia renale cronica nel terzo trimestre 2025 e i dati del trial di Fase 2 HORIZON su MZE829 per la malattia renale mediata da APOL1 nel primo trimestre 2026. L'azienda dichiara una solida posizione finanziaria con liquidità sufficiente fino alla seconda metà del 2027.
Maze Therapeutics (NASDAQ:MAZE) ha designado con efecto inmediato a Misbah Tahir como Director Financiero. Tahir aporta más de 20 años de experiencia en la industria biofarmacéutica y, hasta hace poco, fue CFO en IGM Biosciences, donde lideró la salida a bolsa y captó más de 1.000 millones de dólares en financiación.
El nombramiento se produce mientras Maze se prepara para hitos clínicos clave, incluidos los datos de MZE782 en fenilcetonuria y enfermedad renal crónica en el tercer trimestre de 2025 y los datos del ensayo Fase 2 HORIZON de MZE829 en enfermedad renal mediada por APOL1 en el primer trimestre de 2026. La compañía mantiene una posición financiera sólida con caja suficiente hasta la segunda mitad de 2027.
Maze Therapeutics (NASDAQ:MAZE)는 즉시 발령으로 Misbah Tahir를 최고재무책임자(CFO)로 임명했습니다. Tahir는 바이오제약 업계에서 20년 이상의 경험을 보유하고 있으며, 최근에는 IGM Biosciences의 CFO로 재직하며 회사의 기업공개(IPO)를 주도하고 10억 달러 이상을 조달했습니다.
이번 임명은 Maze가 주요 임상 마일스톤을 앞두고 이루어졌습니다. 여기에는 2025년 3분기 MZE782의 페닐케톤뇨증 및 만성 신장질환 데이터와 2026년 1분기 APOL1 매개 신장질환 대상 MZE829의 2상 HORIZON 시험 데이터가 포함됩니다. 회사는 2027년 하반기까지 이어질 현금 유동성을 보유한 견실한 재무 상태를 유지하고 있습니다.
Maze Therapeutics (NASDAQ:MAZE) a nommé Misbah Tahir au poste de directeur financier (CFO), avec effet immédiat. Tahir apporte plus de 20 ans d'expérience dans l'industrie biopharmaceutique et était récemment CFO chez IGM Biosciences, où il a piloté l'introduction en bourse et levé plus d'un milliard de dollars.
Cette nomination intervient alors que Maze se prépare à des étapes cliniques importantes, notamment les données de MZE782 en phénylcétonurie et maladie rénale chronique au 3e trimestre 2025 et les données de l'essai de phase 2 HORIZON de MZE829 en maladie rénale médiée par APOL1 au 1er trimestre 2026. La société conserve une solide position financière avec une trésorerie couvrant jusqu'à la 2e moitié de 2027.
Maze Therapeutics (NASDAQ:MAZE) hat Misbah Tahir mit sofortiger Wirkung zum Chief Financial Officer ernannt. Tahir verfügt über mehr als 20 Jahre Erfahrung in der biopharmazeutischen Branche und war zuletzt CFO bei IGM Biosciences, wo er den Börsengang leitete und mehr als 1 Milliarde US-Dollar an Kapital einwarb.
Die Ernennung erfolgt, während Maze sich auf wichtige klinische Meilensteine vorbereitet, darunter die Daten zu MZE782 bei Phenylketonurie und chronischer Nierenerkrankung im 3. Quartal 2025 sowie die Phase-2-HORIZON-Daten zu MZE829 bei APOL1-vermittelter Nierenerkrankung im 1. Quartal 2026. Das Unternehmen verfügt über eine solide Finanzlage mit liquiden Mitteln bis in die 2. Hälfte 2027.
- Strong cash runway extending into 2H 2027
- Multiple near-term clinical catalysts expected in Q3 2025 and Q1 2026
- New CFO brings extensive experience in IPOs, capital raising, and pharma partnerships
- Advanced clinical pipeline in kidney and metabolic diseases
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Misbah Tahir as chief financial officer (CFO), effective immediately.
“We’re thrilled to welcome Misbah as Maze’s Chief Financial Officer at such a pivotal time for the company. We are preparing for several key milestones, including data for MZE782 in phenylketonuria and chronic kidney disease in Q3 2025 and initial data from our Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease in Q1 2026,” said Jason Coloma, Ph.D., chief executive officer of Maze. “Misbah’s proven track record in scaling biotech companies, combined with deep financial and operational expertise, will be instrumental in driving our growth strategy as we maintain our focus on clinical execution.”
Mr. Tahir brings more than 20 years of financial and strategic experience in the biopharmaceutical industry. He most recently served as CFO of IGM Biosciences, Inc., where he helped lead the company’s 2019 initial public offering and worked with the executive team to raise more than
“Maze’s strong balance sheet and expected cash runway into 2H 2027, combined with its differentiated precision genetics platform, advancing clinical pipeline, and disciplined development approach have given the company the opportunity to create significant value for both patients and shareholders,” said Mr. Tahir. “I look forward to partnering with Jason and the entire leadership team to drive the next phase for Maze as we work together to harness the power of human genetics to develop potentially novel, small molecule precision medicines for patients with kidney and metabolic diseases.”
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance oral small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, an oral APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease, and MZE782, an oral SLC6A19 inhibitor advancing through Phase 1 with the potential to treat both chronic kidney disease (CKD) and phenylketonuria (PKU). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow the company on LinkedIn and X.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning the company’s future plans and prospects, any expectations regarding the safety or efficacy of MZE829, MZE782 and other candidates under development, the ability of MZE829 to treat AMKD or other indications, the ability of MZE782 to treat CKD, PKU or other indications, the planned timing of the company’s clinical trials, data results and further development of MZE829, MZE782 and other therapeutic candidates, and the ability to drive financial results and stockholder value. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the company believes the expectations reflected in such forward-looking statements are reasonable, the company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the company’s forward-looking statements due to a variety of factors, including risks and uncertainties related to the company’s ability to advance MZE829, MZE782 and its other therapeutic candidates, obtain regulatory approval of and ultimately commercialize the company’s therapeutic candidates, the timing and results of preclinical studies and clinical trials, the company’s ability to fund development activities and achieve development goals, its ability to protect its intellectual property, general business and economic conditions, and risks related to the impact on its business of macroeconomic conditions, including inflation, volatile interest rates, tariffs, instability in the global banking sector, and public health crises. Further information on potential risk factors that could affect the company’s business and its financial results are detailed under the heading “Risk Factors” included in the documents the company files from time to time with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
IR/Corporate Contact:
Amy Bachrodt, Maze Therapeutics
abachrodt@mazetx.com
Media Contact:
Amanda Lazaro, 1AB Media
Amanda@1ABMedia.com
FAQ
Who is the new CFO of Maze Therapeutics (MAZE)?
What are the upcoming clinical milestones for Maze Therapeutics (MAZE) in 2025-2026?
What is Maze Therapeutics' (MAZE) current cash runway?
What is Misbah Tahir's previous experience before joining Maze Therapeutics?
What therapeutic areas does Maze Therapeutics (MAZE) focus on?
